AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00479362 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Implantable Cardioverter-defibrillator
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
Study NCT00479362 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Cardioverter-defibrillator
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
Study NCT04819828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy
Description: A single session of extracorporeal shock wave lithotripsy: the session will be finished upon reaching a maximum of 4,000 shocks or if a complete fragmentation of the kidney stone is observed.
Study NCT04819828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy
Description: A single session of extracorporeal shock wave lithotripsy: the session will be finished upon reaching a maximum of 4,000 shocks or if a complete fragmentation of the kidney stone is observed.
Study NCT04819828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Standard treatment for analgesia: oral diclofenac (75 mg/12 h) as needed.
Study NCT04819828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Standard treatment for analgesia: oral diclofenac (75 mg/12 h) as needed.
Study NCT04819828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Oral tamsulosin (0.4 mg/day) for eight weeks.
Study NCT01690962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegan diet and vitamin B12 supplement
Description: A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
Study NCT01189253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT01690962 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 supplement
Description: A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
Study NCT01094899 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiography
Description: Radiography, microscanner, osteodensitometry
Study NCT01094899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine and Blood sampling
Description: mainly dosage of bones metabolism
Study NCT01094899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echography
Description: body bones echography
Study NCT02077712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: 1 or 2 ug/kg of intranasal dexmedetomidine
Study NCT04151641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNGDPF
Description: Standardized mangosteen extract in dry powder form
Study NCT04151641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNGEF
Description: Standardized mangosteen extract in encapsulated form
Study NCT01933425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Study NCT01933425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rocuronium
Study NCT01933425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Study NCT01933425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugammadex
Study NCT01933425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT01933425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01187875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Fiber free control
Description: Dextrin control administered in a muffin treatment.
Study NCT05659121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic exoskeleton training
Description: robotic exoskeleton training using EksoGT will be incorporated into subject's conventional physiotherapy training.
Study NCT04445077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia Competence Education for care home setting
Description: The intervention is a competency-based education program for care home staff who provide dementia care in Mainland China.
Study NCT04445077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Printed educational materials
Description: The educational materials will be delivered to the participants in the control group for their self-study.
Study NCT02862210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
Study NCT02862210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
Study NCT01962662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Description: EMG biofeedback assisted tibialis anterial force level control
Study NCT01962662 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: U/E exercise
Description: strengthening and stretching
Study NCT01667744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: 10 mg/day
Study NCT01667744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram
Description: 10 mg/day
Study NCT06456723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FET-βAG-TOCA
Description: Single I.V. administration of a \[18F\]fluoroethyl triazole \[Tyr3\]Octreotate (\[18F\]-FET-βAG-TOCA) - maximum injected dose of 370MBq - followed PET/CT imaging.
Study NCT04341610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Product
Description: 100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline
Study NCT04341610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stem Cell Product
Description: 100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline
Study NCT00248677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Family-Based Intervention
Description: Behavioral family intervention
Study NCT00248677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent-Based Intervention
Description: Behavioral Parent-Only Intervention
Study NCT02440724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Winged stent (partially covered)
Description: A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
Study NCT02440724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Winged stent (uncovered)
Description: A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
Study NCT04346225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized C13
Description: Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes
Study NCT01187875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hi-maize resistant starch 9g
Description: 9g Hi-maize resistant starch administered in a muffin treatment.
Study NCT01187875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novalose 330 resistant starch 9g
Description: 9g Novalose 330 resistant starch administered in a muffin treatment.
Study NCT01187875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4.5g Hi-maize resistant starch and 4.5g Novalose 330
Description: 4.5g Hi-maize and 4.5g Novalose 330 in a muffin treatment.
Study NCT01623284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 PiB
Description: One time intravenous administration of 740 megabecquerel (MBq) of \[N-methyl-11C\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
Study NCT01623284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FDG
Description: One time intravenous administration of 629 megabecquerel (MBq) of \[18-F\]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
Study NCT03830411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
Study NCT03830411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
Study NCT03830411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
Study NCT00398905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 2,5 mg twice daily (5 mg total daily dose)
Study NCT04346225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body
Study NCT03595800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hematopoietic stem cells transplantation
Description: Allogeneic Hematopoietic stem cells transplantation
Study NCT03595800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cells transplantation
Description: Allogeneic Hematopoietic stem cells transplantation
Study NCT05124366 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: dental prophylaxis + oral hygiene instructions
Description: Follow up: 2 weeks and 4 weeks
Study NCT05124366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental prophylaxis + oral hygiene instructions
Description: Follow up: 2 weeks and 4 weeks
Study NCT02376114 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ginkgo biloba
Description: The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of Ginkgo or a placebo twice daily by mouth for two weeks. The placebo consisted of 40 mg of corn starch. Ginkgo and the placebo were encapsulated to ensure identical appearance.
Study NCT02376114 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to Ginkgo biloba
Study NCT03933592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior block
Description: after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally, until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 mint before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
Study NCT03933592 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural
Description: In group I: thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
Study NCT00974558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: handheld fan directed to cheeks
Description: Handheld fan directed to cheeks for 5 minutes
Study NCT04570748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsule repair
Description: Direct anterior hip arthroplasty with or without capsule repair
Study NCT04570748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: capsulectomy
Description: capsulectomy without repair
Study NCT02802852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic calf compression
Description: Application of a pneumatic calf compression device for two hours per day, every day for 30 days.
Study NCT02802852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administration of Filgrastim 10 mcg/kg every 3rd day for 30 days
Study NCT04456972 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: One arm only
Description: Samples of plasma to analyze ctDNA
Study NCT04426851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: BI 1358894
Study NCT04040062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
Study NCT01905215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003892A (formulation 1)
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
Study NCT01905215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003893A (formulation 2)
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
Study NCT01905215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003895A (formulation 3)
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
Study NCT01905215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003896A (formulation 4)
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
Study NCT01905215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003898A (formulation 5)
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
Study NCT01905215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003899A (formulation 6)
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
Study NCT01905215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
Study NCT00398905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 5 mg twice daily (10 mg total daily dose)
Study NCT00398905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 10 mg twice daily (20 mg total daily dose)
Study NCT00398905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 20 mg twice daily (40 mg total daily dose)
Study NCT00398905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 30 mg twice daily (60 mg total daily dose)
Study NCT00398905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg once daily (40 mg total daily dose)
Study NCT02616952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese herbal therapy
Description: Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks. The Yiqi Suoquan Tang are composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g. All the decoctions are provided by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and are packed in opaque plastic bags with 200 ml for each one.
Study NCT02951858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.
Study NCT02951858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The participants only receive the materials about the harm of substance use.
Study NCT03090880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin Sodium
Description: Subcutaneous tinzaparin 4,500 IU once daily for six months.
Study NCT00871858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: Given orally
Study NCT00871858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given intramuscularly
Study NCT02616952 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pelvic floor muscle training
Description: In intensive exercises, participants are taught how to identify the muscles: 1) identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2) identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; 3) contract levator ani with a position of sitting, lying, and standing; 4) contract anal sphincter with a position of sitting, lying, and standing. Once the participants can identify the muscles, they are asked to do a set consists of 10 contractions, each lasting 5 seconds, with a 5 seconds break between contractions. Then they need to do same procedure 3 times daily as the home exercises.
Study NCT01366963 — intervention group
Intervention type: BEHAVIORAL
Intervention: Seated Measurements
Description: The following measurements will take place in a seated position:~Ruff 1 \& 7 (visual search and attention processes) Trails A \& B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)
Study NCT01366963 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standing Measurements
Description: The following will be measured in a standing position (at least 5 minutes)~Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160Eu/0.5ml in adults
Description: inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320Eu/0.5ml in adults
Description: inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640Eu/0.5ml in adults
Description: inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1280Eu/0.5ml (without adjuvant) in 12 adults
Description: inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0Eu/0.5ml in adults
Description: 0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160Eu/0.5ml in children
Description: inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320Eu/0.5ml in children
Description: inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.